Financials

Company Profile

Redpoint Bio Corp is a United States-based company. The Company is engaged in research and development in physical, engineering and life sciences.

Employees

Sector

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

13-07-16	Redpoint Bio Corporation cancelled the transaction announced on July 16, 2012.	CI
12-08-09	Redpoint Bio Corporation cancelled the acquisition of Celator Pharmaceuticals, Inc. from Domain Associates, L.L.C., BDC Diversified Venture Fund of BDC Venture Capital, GrowthWorks Access Fund Limited Partnership of Matrix Asset Management Inc., Quaker BioVentures, Thomas, McNerney & Partners, TL Ventures, Ventures West Management Inc. and others.	CI

13-07-16	Redpoint Bio Corporation cancelled the transaction announced on July 16, 2012.	CI
12-08-09	Redpoint Bio Corporation cancelled the acquisition of Celator Pharmaceuticals, Inc. from Domain Associates, L.L.C., BDC Diversified Venture Fund of BDC Venture Capital, GrowthWorks Access Fund Limited Partnership of Matrix Asset Management Inc., Quaker BioVentures, Thomas, McNerney & Partners, TL Ventures, Ventures West Management Inc. and others.	CI
12-07-16	Redpoint Bio Corporation announced that it expects to receive $40 million in funding.	CI
12-06-17	Redpoint Bio Corporation entered into an exchange transaction agreement to acquire Celator Pharmaceuticals, Inc. from Domain Associates, L.L.C., BDC Diversified Venture Fund of BDC Venture Capital, GrowthWorks Access Fund Limited Partnership of Matrix Asset Management Inc., Quaker BioVentures, Thomas, McNerney & Partners, TL Ventures, Ventures West Management Inc. and others.	CI
12-04-16	Redpoint Bio Corporation Auditor Raises 'Going Concern' Doubt	CI
12-01-26	Redpoint Bio Corporation Announces Resignation of F. Raymond Salemme as Member of the Board of Directors, Effective as of January 31, 2012	CI

10-11-09	REDPOINT BIO CORP : Redpoint Bio Reports Three Months and Nine Months Ended September 30, 2010 Results	PR
10-11-03	REDPOINT BIO CORP : Redpoint Announces Generally Recognized As Safe (GRAS) Determination for RP44 Sweetness Enhancer	PR
10-09-07	REDPOINT BIO CORP : Redpoint Bio to Present at Rodman & Renshaw Annual Global Investment Conference	PR
10-08-13	REDPOINT BIO CORP : Redpoint Bio Reports Three Months and Six Months Ended June 30, 2010 Results	PR
10-07-28	REDPOINT BIO CORP : Redpoint Bio Receives U.S. Patent Covering Screening Technology	PR

Manager	Title	Age	Since
Scott M. Horvitz CEO	Chief Executive Officer	67	2007-03-11
Susan M. Welsh PSD	President	-	-

Director	Title	Age	Since
Robert M. Chefitz BRD	Director/Board Member	66	-
Lars Dybkjær BRD	Director/Board Member	-	-
David Patchen BRD	Director/Board Member	72	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REDPOINT BIO CORPORATION	-.--%	-.--%	-	-	7.99K
LONZA GROUP AG	+0.12%	+1.74%	+2.10%	+8.66%	49.42B
REVOLUTION MEDICINES, INC.	-0.36%	+1.21%	+420.77%	+619.10%	40.34B
IQVIA HOLDINGS INC.	-2.13%	+0.29%	+23.91%	-6.01%	34.01B
BEONE MEDICINES AG	-2.29%	+3.83%	+23.48%	+59.26%	33.56B
CELLTRION, INC.	-0.79%	+1.32%	+5.78%	+36.42%	26.84B
ASCENDIS PHARMA A/S	+3.82%	+3.51%	-	-	17.22B
MEDPACE HOLDINGS, INC.	-2.62%	-2.13%	+64.96%	+125.87%	15.19B
IONIS PHARMACEUTICALS, INC.	-2.17%	+6.65%	+104.31%	+102.15%	13.96B
EUROFINS SCIENTIFIC SE	-0.54%	-3.53%	+11.73%	+17.14%	13.36B
Average	-0.69%	+1.33%	+82.13%	+120.33%	24.39B
Weighted average by Cap.	-0.77%	+1.54%	+94.56%	+139.99%